© 2022 MJH Life Sciences and AJMC. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
January 24, 2022
A presentation at the 63rd American Society of Hematology (ASH) annual meeting explored the collection of real-world data.
The 63rd American Society of Hematology (ASH) Annual Meeting and Exposition featured leading experts who discussed research on multiple myeloma.
Ongoing and new developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 63rd American Society of Hematology (ASH) annual meeting.
Clinical trial results in the leukemia and lymphoma space were covered at the 63rd American Society of Hematology (ASH) annual meeting.
Disparities and inequities in care were topics of interest at the 63rd American Society of Hematology (ASH) annual meeting.
January 20, 2022
Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.
January 18, 2022
There has not been a change in the standard of care in this type of cancer in a decade, according to an expert from ASCO.
Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.
Stephen Schleicher, MD, MBA, and Natalie Dickson, MD, discuss their new roles as chief medical officer (CMO) and chief strategy officer (CSO), respectively, at Tennessee Oncology.